Literature DB >> 20567114

[Long-term survival of a breast cancer patient with liver metastasis treated with trastuzumab and Paclitaxel].

Yohei Ota1, Takashi Ishikawa, Akimitsu Yamada, Daisuke Shimizu, Satoshi Hasegawa, Takashi Chishima, Itaru Endo.   

Abstract

We report a long-term survival case of metastatic breast cancer treated with trastuzumab and paclitaxel. The patient was a 64-year-old female. She underwent right quadrantectomy with axillary lymphadenectomy for advanced breast cancer. Histological examination showed papillotubular carcinoma, f, t2, n1(6/14), ER(-), PgR(-), HER2(3+). CMF and radiation were performed as adjuvant therapy. One year after the operation she was diagnosed to have liver metastasis and initiated trastuzumab treatment. Paclitaxel was also intermittently administered when the tumor marker was elevated. Four years after the operation, she experienced obstructive jaundice and was diagnosed as hepatic portal region metastasis. Obstructive jaundice was promptly alleviated after receiving trastuzumab and vinorelbin. No adverse events were reported over sixty-eight months of trastuzumab treatment. Long-term trastuzumab and intermittent chemotherapy would be one of the optimal treatments for HER2-positive breast cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20567114

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  2 in total

1.  Metastatic human epidermal growth factor 2 (HER2/neu) amplified breast cancer with acute fulminant hepatitis responding to trastuzumab, pertuzumab and carboplatin.

Authors:  Mariela N Macias; Daniel Sanghoon Shin; Blanca Ledezma; Saeed Sadeghi
Journal:  BMJ Case Rep       Date:  2014-06-04

2.  Management of HER2-Positive Breast Cancer for a Young Patient with Visceral Crisis-The Adjuvant Role of Lifestyle Changes.

Authors:  Larisa Maria Badau; Andrei Dorin Ciocoiu; Cristina Marinela Oprean; Nusa Alina Segarceanu; Adelina Gheju; Brigitha Vlaicu
Journal:  Curr Oncol       Date:  2022-03-10       Impact factor: 3.677

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.